Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026

Pasithea Therapeutics (KTTA) will host a virtual expert event on NF1 treatment on November 4, 2026, at 11:00 a.m. ET.

Rhea-AI Summary

Pasithea Therapeutics (KTTA) will host a virtual expert event on NF1 treatment on November 4, 2026, at 11:00 a.m. ET. Rebecca M. Brown and Kavita Sarin will join management to discuss unmet needs and treatments for NF1-associated cutaneous and plexiform neurofibromas. The program will cover PAS-004 and review Phase 1 solid tumor data presented at the ESMO Congress 2026.

Argus 15 min delay 9 alerts

-5.70% vs previous close $0.37 last price 8.3x rel. volume Open Argus

Details

Market Reaction – KTTA

$0.37 – $0.40 Day Range

$12.52M Mkt Cap at Last Price

On Oct 28, the day this news came out, the latest delayed price for KTTA is 5.70% below the previous close. Our momentum scanner has recorded 9 alerts for this stock so far that day. The latest delayed price is $0.37. Relative volume is exceptionally heavy at 8.3x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

key opinion leader, MEK inhibitor, neurofibromatosis type 1, rasopathies

4 terms

key opinion leader technical

"virtual key opinion leader (KOL) event"

A key opinion leader is an individual whose insights, expertise, or influence significantly shape the opinions and decisions of others within a particular field or community. For investors, they are like trusted guides whose views can impact market trends or perceptions, making their perspectives important to watch. Their influence often stems from experience, reputation, or widespread respect among peers.

MEK inhibitor medical

"a next-generation macrocyclic oral MEK inhibitor"

A MEK inhibitor is a drug that blocks MEK enzymes, which act like a relay in a cell’s growth-signaling pathway; by cutting that relay these drugs can slow or stop uncontrolled cell growth seen in some cancers and other proliferative conditions. Investors care because clinical trial outcomes, safety data, and regulatory approvals determine whether a MEK inhibitor becomes a marketable therapy, directly affecting a developer’s revenue prospects and valuation — like a product passing a crucial safety and sales test.

neurofibromatosis type 1 medical

"including neurofibromatosis type 1 (NF1) associated neurofibromas"

A genetic condition that causes noncancerous tumors to grow on nerves and can lead to skin changes, pain, learning challenges and other complications; severity varies widely from mild to serious. Investors track it because treatments, diagnostics and care pathways for this distinct patient group can drive clinical trial outcomes, regulatory approvals and long‑term revenue, much like a niche market where the size, unmet need and treatment complexity determine potential returns.

rasopathies medical

"across a range of RASopathies"

A group of inherited genetic disorders caused by germline mutations that alter the RAS/MAPK cell-signaling pathway, leading to abnormal development and growth. Rasopathies share common features—such as distinctive facial characteristics, heart defects, developmental delays, and an increased risk of certain tumors—but vary in specific symptoms and severity depending on the exact gene mutation; they are distinct from cancers driven by somatic (non‑inherited) RAS mutations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Rebecca M. Brown, MD, and Kavita Sarin, MD, PhD, will join management to discuss unmet needs and the treatment landscape for NF1-associated cutaneous and plexiform neurofibromas

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1) associated neurofibromas, today announced that it will host a virtual key opinion leader (KOL) event, “Rethinking NF1 Treatment: KOL Perspectives on Cutaneous and Plexiform Neurofibromas,” on Wednesday, November 4, 2026, at 11:00 a.m. ET.

The event will feature Rebecca M. Brown, MD, Associate Professor of Neurology at the University of Alabama at Birmingham (UAB), Heersink School of Medicine, and Kavita Sarin, MD, PhD, Professor of Dermatology and Director of the Stanford Skin Cancer Genetics Program at the Stanford Cancer Institute. The KOLs will join company management to discuss unmet medical needs and the current treatment landscape for neurofibromatosis type 1 (NF1)-associated cutaneous neurofibromas (CN) and plexiform neurofibromas (PN).

The program will provide an overview of PAS-004 and its potential across a range of RASopathies, including NF1-associated cutaneous and plexiform neurofibromas. Management will review its Phase 1 solid tumor data presented at the ESMO Congress 2026 and summarize its commercial opportunity across both NF1 disease manifestations.

To register for the webcast, click here. For those unable to attend, a replay will be available here.

About Rebecca M. Brown, MD

Dr. Rebecca M. Brown leads the Neurofibromatosis Clinic at UAB and serves as an Associate Professor of Neurology at the UAB Heersink School of Medicine. She is also a Scientist at the Comprehensive Neuroscience Center and UAB O’Neal Cancer Center. Dr. Brown earned her medical degree from the University of Texas Southwestern Medical School and completed fellowship training at Memorial Sloan Kettering Cancer Center. She is board-certified in Neurology by the American Board of Psychiatry and Neurology. Her experience spans NF laboratory research and clinical trials, including studies involving the RAS-RAF-MEK-ERK (MAPK) pathway.

About Kavita Sarin, MD, PhD

Dr. Kavita Sarin is a Professor of Dermatology and Director of the Stanford Skin Cancer Genetics Program at the Stanford Cancer Institute. Her research focuses on precision medicine, integrating genetic and clinical information to understand disease susceptibility, prognosis, and treatment in skin cancer and rare dermatologic disorders. Dr. Sarin co-leads the Cutaneous Neurofibroma Working Group within the Response Evaluation in Neurofibromatosis & Schwannomatosis (REiNS) collaboration, advancing international efforts to develop core outcome sets, patient-reported outcome measures, and standardized clinical trial endpoints for NF1.

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s clinical data from its ongoing Phase 1 dose-escalation study of PAS-004 in advanced solid tumors, , the Company’s ongoing Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Contact

Patrick Gaynes
Investor Relations
pgaynes@pasithea.com